<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01513499</url>
  </required_header>
  <id_info>
    <org_study_id>MGH1004</org_study_id>
    <nct_id>NCT01513499</nct_id>
  </id_info>
  <brief_title>Effect of Intranasal Oxytocin on Appetite and Caloric Intake in Men and Women</brief_title>
  <official_title>Effect of Intranasal Oxytocin on Appetite and Caloric Intake in Humans</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Exciting advances have led to the concept that hormones can modulate appetite and food
      intake. Oxytocin is a peptide hormone that is released in regions throughout the brain,
      including areas involved in food motivation. Animal studies suggest that oxytocin may reduce
      food intake. The effects of oxytocin administration on eating behavior in humans, which could
      have important implications in eating-related disorders ranging from obesity to anorexia
      nervosa, have not been investigated. This double-blind placebo-controlled cross-over study of
      single-dose oxytocin administration investigates whether:

        1. Caloric intake will decrease following administration of oxytocin versus placebo

        2. Appetite will decrease following administration of oxytocin versus placebo

        3. Resting energy expenditure will increase following administration of oxytocin versus
           placebo
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2012</start_date>
  <completion_date type="Actual">January 2014</completion_date>
  <primary_completion_date type="Actual">January 2014</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Caloric intake</measure>
    <time_frame>+60 minutes after drug/placebo</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Appetite</measure>
    <time_frame>+55 (fasting) and +90 minutes (post-prandial) after drug/placebo</time_frame>
    <description>Assessed using a Visual Analogue Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Resting energy expenditure</measure>
    <time_frame>+30 minutes after drug/placebo</time_frame>
    <description>Assessed using metabolic cart</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Eating Behavior</condition>
  <arm_group>
    <arm_group_label>Oxytocin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intranasal oxytocin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Intranasal placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxytocin</intervention_name>
    <description>Intranasal oxytocin 24 IU single-dose administration</description>
    <arm_group_label>Oxytocin</arm_group_label>
    <other_name>Syntocinon (Novartis)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Intranasal Placebo single-dose administration</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18-45 years old

          -  BMI 18.5-24.9, 25-40

          -  Regular breakfast eater (at least 4 times per week)

          -  Stable weight within the past three months

        Exclusion Criteria:

          -  Psychiatric disease

          -  Use of psychotropic medications

          -  History of eating disorder

          -  History of excessive exercise within the last three months

          -  History of diabetes mellitus

          -  Active substance abuse

          -  Hematocrit below normal range

          -  Gastrointestinal tract surgery (including gastrectomy, gastric bypass surgery, and
             small or large bowel resection)

          -  History of cardiovascular disease (such as hypertrophic cardiomyopathy, valvular heart
             disease, coronary heart disease, or coronary artery spasms)

          -  Untreated thyroid disease

          -  Tobacco use
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elizabeth A Lawson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 11, 2012</study_first_submitted>
  <study_first_submitted_qc>January 19, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 20, 2012</study_first_posted>
  <last_update_submitted>February 15, 2018</last_update_submitted>
  <last_update_submitted_qc>February 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Elizabeth Austen Lawson</investigator_full_name>
    <investigator_title>Assistant in Medicine</investigator_title>
  </responsible_party>
  <keyword>Eating behavior</keyword>
  <keyword>Appetite</keyword>
  <keyword>Oxytocin</keyword>
  <keyword>Neuropeptide</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxytocin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

